跳至主要内容
临床试验/CTRI/2020/10/028635
CTRI/2020/10/028635尚未招募2 期

Clinical evaluation of Virunil a standardized ayurvedic herbal compound as an adjuvant in management of COVID-19

RI ACADEMY OF SCIENCES0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures.
  • Patient who are present in the stages of 1 and 2 of the COVID-19 disease.

排除标准

  • 1.Patients with Auto Immune Disorders.
  • 2.Patients with Co morbid conditions such as Diabetes Mellitus and Hypertension.
  • 3.Patients Under any kind of Anti-Cancer medication, Immunosuppressants.
  • 4.Patients who are under anti-platelet medication.
  • 5.Patients with history of Organ Transplantation.
  • 6.Patients with compromised pulmonary function.
  • 7.Patients receiving antiviral drugs.
  • 8.Pregnant and lactating mothers are also excluded from the study.
  • 9.Any other condition, where investigators jeopardize the outcomes of the trials

研究者

发起方
RI ACADEMY OF SCIENCES

相似试验

use of VIRUNIL an Ayurvedic medicie as a supportive... | 临床试验